Skip to main content
. 2019 Mar 21;17(6):5139–5146. doi: 10.3892/ol.2019.10183

Table I.

Patient characteristics.

Category Patients, n (total 55) %
Pathological T factor
  1a 0 0.0
  1b 1 1.8
  1c 21 38.2
  2 25 45.5
  3 2 3.6
  4a 0 0.0
  4b 6 10.9
Pathological N factor
  0 35 63.6
  1a 13 23.6
  1b 0 0.0
  1c 0 0.0
  2a 6 11.0
  2b 0 0.0
  3a 0 0.0
  3b 1 1.8
  3c 0 0.0
Tumor-Node-Metastasis stage
  IA 17 31.0
  IB 0 0.0
  IIA 18 32.7
  IIB 7 12.7
  IIIA 7 12.7
  IIIB 5 9.1
  IIIC 1 1.8
Pathological subtype
  Papillo-tubular 18 32.7
  Solid-tubular 9 16.4
  Scirrhous 25 45.4
  Other 3 5.5
Histological grade
  1 24 43.6
  2 17 30.9
  3 11 20.0
  Not graded 3 5.5
Molecular subtype
  Luminal A-like 19 34.5
  Luminal B/HER- 9 16.4
  Luminal B/HER+ 15 27.3
  HER2 4 7.3
  Triple-negative 8 14.5
Surgical procedure
  Bp+SN 19 34.5
  Bp+AX 8 14.5
  Bt+SN 11 20.0
  Bt+AX 17 31.0

Luminal B/HER-, Luminal B-like human epidermal receptor 2 negative; Luminal B/HER+, Luminal B-like human epidermal receptor 2 positive; Bp+SN, partial mastectomy with sentinel node biopsy; Bp+AX, partial mastectomy with axillary lymph node dissection; Bt+SN, modified radical mastectomy with sentinel node biopsy; Bt+AX, modified radical mastectomy with axillary lymph node dissection.